GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (FRA:RER1) » Definitions » Price-to-Free-Cash-Flow

Recordati SpA (FRA:RER1) Price-to-Free-Cash-Flow : N/A (As of May. 24, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Recordati SpA Price-to-Free-Cash-Flow?

As of today (2025-05-24), Recordati SpA's share price is €50.60. Recordati SpA's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.28. Hence, Recordati SpA's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Recordati SpA's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Recordati SpA's highest Price-to-Free-Cash-Flow Ratio was 108.58. The lowest was 17.44. And the median was 25.84.

FRA:RER1's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Recordati SpA's Free Cash Flow per Share for the three months ended in Mar. 2025 was €0.75. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-1.28.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Recordati SpA was -274.50% per year.

During the past 13 years, Recordati SpA's highest 3-Year average Free Cash Flow per Share Growth Rate was 76.50% per year. The lowest was -27.90% per year. And the median was 13.15% per year.


Recordati SpA Price-to-Free-Cash-Flow Historical Data

The historical data trend for Recordati SpA's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Price-to-Free-Cash-Flow Chart

Recordati SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.84 29.21 22.18 100.06 -

Recordati SpA Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.81 89.52 22.44 - -

Competitive Comparison of Recordati SpA's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Recordati SpA's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Price-to-Free-Cash-Flow falls into.


;
;

Recordati SpA Price-to-Free-Cash-Flow Calculation

Recordati SpA's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=50.60/-1.281
=N/A

Recordati SpA's Share Price of today is €50.60.
Recordati SpA's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.28.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Recordati SpA  (FRA:RER1) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Recordati SpA Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA Business Description

Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.

Recordati SpA Headlines

No Headlines